its incidence is rising steadily in developing nations. The patient prognosis for CRC remains poor,despite advances in surgery and treatment. Additionally, there are currently no reliable prognosticapproaches for CRC, despite the use of conventional prognostic factors. Immune checkpointsblockades (ICB) have emerged as a promising treatment strategy and have dramatically improvedlong-term survival in several malignances. The “PD-1 (programmed cell death-1)”/PD-L1(programmed cell death-ligand 1) axis plays an important role to control immune suppression bydown-regulating T effector cell activities enable tumor cells to escape from the host’s anti-tumorimmune surveillance. Aim of this study was to evaluate the expression of PD-L1 (28-8 clone) inresected samples of colorectal cancer.Methods: This was a cross-sectional observational study. A total 64 cases were selected from thepatients who were diagnosed as adenocarcinoma from resected samples received in the departmentof pathology at BSMMU from July 2021 to June 2023. Immuno-histochemical staining for PD-L1was performed along with appropriate positive control.Results: In this study PD-L1 immuno-expression was found in 14 (21.9%) out of 64 cases.However, no expression was found in rest of the 50 (78.1%) cases.Conclusion: Evaluation of expression of PD-L1 may emerge as a new marker and target for theimmunotherapy of colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Jahan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: